Juvia Bio

Juvia Bio (operating as Juvia Therapeutics in clinical development) is a biotechnology company specializing in the development of novel therapeutics that target the gut-brain axis to treat neurodegenerative and neuropsychiatric disorders. Founded by Dr. Thomas Borody, a pioneer in fecal microbiota transplantation, the company leverages microbial insights to identify specific signatures and metabolites that influence central nervous system health. Their lead clinical program, JUV-101, is a live biotherapeutic product aimed at modifying disease progression in Parkinson's disease by addressing gut-derived triggers of neuroinflammation. In addition to its clinical pipeline, the company markets consumer gut health products based on its proprietary enzyme-rich malt extract technology. Juvia Bio utilizes a discovery platform to translate complex microbial interactions into standardized medical treatments and is currently advancing multiple programs through early-stage clinical and preclinical research.